Severity of psoriasis and its impact on patient-reported outcomes (PROs): real world evidence with brodalumab 210 mg from the LIBERO study
Aim Only limited data is available on the benefit of brodalumab 210 mg, an IL-17 receptor A antagonist, on patient-reported outcomes (PROs) in different psoriasis severity groups under real-world-evidence (RWE) conditions.Methods LIBERO, a prospective, multicenter, 12- and 52-weeks (W) non-intervent...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2025-12-01
|
| Series: | Journal of Dermatological Treatment |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/09546634.2025.2500511 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850216785459019776 |
|---|---|
| author | Matthias Augustin Rudolf E. Schopf Sven R. Quist Nalan Kalyon Ralph M. von Kiedrowski |
| author_facet | Matthias Augustin Rudolf E. Schopf Sven R. Quist Nalan Kalyon Ralph M. von Kiedrowski |
| author_sort | Matthias Augustin |
| collection | DOAJ |
| description | Aim Only limited data is available on the benefit of brodalumab 210 mg, an IL-17 receptor A antagonist, on patient-reported outcomes (PROs) in different psoriasis severity groups under real-world-evidence (RWE) conditions.Methods LIBERO, a prospective, multicenter, 12- and 52-weeks (W) non-interventional study on brodalumab in adult patients with plaque-type psoriasis assessed its short- and long-term impact on PROs in mild, moderate and severe psoriasis defined by Psoriasis Area Severity Index (PASI).Results 200 (31.3%) patients with severe (PASI ≥ 20), 263 (41.2%) with moderate (PASI = 10–19) and 168 (26.3%) with mild (PASI < 10) psoriasis were analyzed. In all severity groups a rapid and sustained reduction of mean(m) PASI was observed as of W2. 76.7, 84.9 and 82.0% of patients assessed their psoriasis as being clear/almost clear in mild, moderate and severe subgroups and mean Dermatological Life Quality Index improved from 11.2, 14.3 and 17.1 to 3.2, 2.9 and 3.8. 73.7% of patients rated brodalumab as being quite/very beneficial (Patient Benefit Index, PBI) and were quite/very satisfied with the treatment (TSQM-9). Regaining disease control and reducing physical impairment achieved highest PBI-scores.Conclusion LIBERO confirms the benefit of brodalumab on PROs including rapid and complete clearance of skin lesions, quality of life and individual patient benefits – irrespective of their disease severity. |
| format | Article |
| id | doaj-art-6697c5da360f4dbda2eed0317d05a011 |
| institution | OA Journals |
| issn | 0954-6634 1471-1753 |
| language | English |
| publishDate | 2025-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Journal of Dermatological Treatment |
| spelling | doaj-art-6697c5da360f4dbda2eed0317d05a0112025-08-20T02:08:13ZengTaylor & Francis GroupJournal of Dermatological Treatment0954-66341471-17532025-12-0136110.1080/09546634.2025.2500511Severity of psoriasis and its impact on patient-reported outcomes (PROs): real world evidence with brodalumab 210 mg from the LIBERO studyMatthias Augustin0Rudolf E. Schopf1Sven R. Quist2Nalan Kalyon3Ralph M. von Kiedrowski4German Center for Health Services Research in Dermatology (CVderm), Institute for Health Services Research in Dermatology and Nursing (IVDP), University Medical Center Hamburg-Eppendorf (UKE), Hamburg, GermanyDepartment of Dermatology and Venerology, Johannes Gutenberg University of Mainz, GermanyDermatological Practice, Mainz, GermanyLEO Pharma GmbH, Neu-Isenburg, GermanyMedical Study & Service Selters GmbH and Private Practice, Selters, GermanyAim Only limited data is available on the benefit of brodalumab 210 mg, an IL-17 receptor A antagonist, on patient-reported outcomes (PROs) in different psoriasis severity groups under real-world-evidence (RWE) conditions.Methods LIBERO, a prospective, multicenter, 12- and 52-weeks (W) non-interventional study on brodalumab in adult patients with plaque-type psoriasis assessed its short- and long-term impact on PROs in mild, moderate and severe psoriasis defined by Psoriasis Area Severity Index (PASI).Results 200 (31.3%) patients with severe (PASI ≥ 20), 263 (41.2%) with moderate (PASI = 10–19) and 168 (26.3%) with mild (PASI < 10) psoriasis were analyzed. In all severity groups a rapid and sustained reduction of mean(m) PASI was observed as of W2. 76.7, 84.9 and 82.0% of patients assessed their psoriasis as being clear/almost clear in mild, moderate and severe subgroups and mean Dermatological Life Quality Index improved from 11.2, 14.3 and 17.1 to 3.2, 2.9 and 3.8. 73.7% of patients rated brodalumab as being quite/very beneficial (Patient Benefit Index, PBI) and were quite/very satisfied with the treatment (TSQM-9). Regaining disease control and reducing physical impairment achieved highest PBI-scores.Conclusion LIBERO confirms the benefit of brodalumab on PROs including rapid and complete clearance of skin lesions, quality of life and individual patient benefits – irrespective of their disease severity.https://www.tandfonline.com/doi/10.1080/09546634.2025.2500511IL-17RA antagonistnon-interventional studypatient-reported outcomes (PROs)patient needspatient benefitsquality of life |
| spellingShingle | Matthias Augustin Rudolf E. Schopf Sven R. Quist Nalan Kalyon Ralph M. von Kiedrowski Severity of psoriasis and its impact on patient-reported outcomes (PROs): real world evidence with brodalumab 210 mg from the LIBERO study Journal of Dermatological Treatment IL-17RA antagonist non-interventional study patient-reported outcomes (PROs) patient needs patient benefits quality of life |
| title | Severity of psoriasis and its impact on patient-reported outcomes (PROs): real world evidence with brodalumab 210 mg from the LIBERO study |
| title_full | Severity of psoriasis and its impact on patient-reported outcomes (PROs): real world evidence with brodalumab 210 mg from the LIBERO study |
| title_fullStr | Severity of psoriasis and its impact on patient-reported outcomes (PROs): real world evidence with brodalumab 210 mg from the LIBERO study |
| title_full_unstemmed | Severity of psoriasis and its impact on patient-reported outcomes (PROs): real world evidence with brodalumab 210 mg from the LIBERO study |
| title_short | Severity of psoriasis and its impact on patient-reported outcomes (PROs): real world evidence with brodalumab 210 mg from the LIBERO study |
| title_sort | severity of psoriasis and its impact on patient reported outcomes pros real world evidence with brodalumab 210 mg from the libero study |
| topic | IL-17RA antagonist non-interventional study patient-reported outcomes (PROs) patient needs patient benefits quality of life |
| url | https://www.tandfonline.com/doi/10.1080/09546634.2025.2500511 |
| work_keys_str_mv | AT matthiasaugustin severityofpsoriasisanditsimpactonpatientreportedoutcomesprosrealworldevidencewithbrodalumab210mgfromtheliberostudy AT rudolfeschopf severityofpsoriasisanditsimpactonpatientreportedoutcomesprosrealworldevidencewithbrodalumab210mgfromtheliberostudy AT svenrquist severityofpsoriasisanditsimpactonpatientreportedoutcomesprosrealworldevidencewithbrodalumab210mgfromtheliberostudy AT nalankalyon severityofpsoriasisanditsimpactonpatientreportedoutcomesprosrealworldevidencewithbrodalumab210mgfromtheliberostudy AT ralphmvonkiedrowski severityofpsoriasisanditsimpactonpatientreportedoutcomesprosrealworldevidencewithbrodalumab210mgfromtheliberostudy |